Fox Run Management L.L.C. Raises Position in Jazz Pharmaceuticals PLC $JAZZ

Key Points

• Fox Run Management L.L.C. increased its stake in Jazz Pharmaceuticals by 133.9% during the first quarter, now owning 10,339 shares valued at approximately $1.28 million.
• Jazz Pharmaceuticals reported earnings per share of ($8.25) for the last quarter, missing analyst estimates, despite achieving revenue of $1.05 billion.
• Analyst price targets for Jazz Pharmaceuticals have been adjusted downward, with recent estimates ranging from $147.00 to $182.00 amidst varying ratings, including several maintain "buy" and "outperform" designations.

Fox Run Management L.L.C. increased its stake in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) by 133.9% in the 1st quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 10,339 shares of the specialty pharmaceutical company's stock after acquiring an additional 5,918 shares during the quarter. Fox Run Management L.L.C.'s holdings in Jazz Pharmaceuticals were worth $1,284,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in JAZZ. Boston Partners lifted its position in shares of Jazz Pharmaceuticals by 21.6% during the first quarter. Boston Partners now owns 11,150 shares of the specialty pharmaceutical company's stock worth $1,384,000 after purchasing an additional 1,978 shares in the last quarter. Caitong International Asset Management Co. Ltd acquired a new stake in shares of Jazz Pharmaceuticals in the first quarter valued at $80,000. Prudential PLC acquired a new position in Jazz Pharmaceuticals during the first quarter valued at $518,000. Nuveen LLC acquired a new stake in Jazz Pharmaceuticals in the 1st quarter valued at approximately $62,362,000. Finally, Cooper Financial Group increased its holdings in Jazz Pharmaceuticals by 4.2% in the first quarter. Cooper Financial Group now owns 4,518 shares of the specialty pharmaceutical company's stock valued at $561,000 after purchasing an additional 184 shares during the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Analyst Upgrades and Downgrades

JAZZ has been the topic of a number of research analyst reports. Wall Street Zen downgraded Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Jazz Pharmaceuticals in a research report on Tuesday, July 15th. They set a "buy" rating and a $152.00 price target for the company. Robert W. Baird reduced their price target on shares of Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Piper Sandler reissued an "overweight" rating and set a $147.00 price target (down previously from $176.00) on shares of Jazz Pharmaceuticals in a research report on Wednesday, May 7th. Finally, Royal Bank Of Canada reduced their price target on shares of Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating for the company in a research report on Wednesday, May 7th. Thirteen research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company. According to MarketBeat, Jazz Pharmaceuticals currently has an average rating of "Moderate Buy" and an average price target of $181.43.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, CEO Bruce C. Cozadd sold 1,000 shares of Jazz Pharmaceuticals stock in a transaction on Tuesday, July 1st. The shares were sold at an average price of $107.63, for a total transaction of $107,630.00. Following the transaction, the chief executive officer owned 436,973 shares in the company, valued at approximately $47,031,403.99. The trade was a 0.23% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Stock Performance

Shares of Jazz Pharmaceuticals stock traded up $1.53 on Tuesday, hitting $119.20. 562,528 shares of the company's stock were exchanged, compared to its average volume of 959,322. The company has a debt-to-equity ratio of 1.17, a quick ratio of 1.37 and a current ratio of 1.62. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a 50-day simple moving average of $111.94 and a 200-day simple moving average of $117.12. The stock has a market capitalization of $7.23 billion, a PE ratio of -17.73, a PEG ratio of 7.42 and a beta of 0.34.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last released its earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts' consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The firm had revenue of $1.05 billion for the quarter, compared to analysts' expectations of $1.05 billion. During the same quarter last year, the firm posted $5.30 EPS. The firm's quarterly revenue was up 2.1% compared to the same quarter last year. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. As a group, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.